Volatus Aerospace Inc. Secures $3 Million in Financing from Existing Major Institutional Investor and Provides Corporate Update
/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, June 19, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”), a leader in global aerial solutions, is pleased to announce the successful closing of a $3 million private placement (the “Financing”) from Investissement Québec. Pursuant to the Financing, the Company entered into an amended and restated secured convertible debenture (the “Debenture”) increasing the principal amount of Investissement Québec's original investment of $7.5 million, as announced in the Company's news release dated October 21, 2024, to an aggregate of $10.5 million.
Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia
Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year 1 with 60% of patients experiencing relapse or death within 12 months 2 Management releases Virtual Investor “What This Means” segment; Access here SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML.
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib
Volatus Releases Q1 2025 Financial Results
Generated revenue of $5,713,158 in Q1 2025 Achieved 30% EBITDA improvement over Q1 2024 Continuation of optimization efforts post Volatus and Drone Delivery Canada merger of equals Subsequent to quarter end, closed $3,000,000 fully subscribed LIFE Offering Subsequent to quarter end, announced closing of shares for debt transaction of $2,646,000 and an additional $446,400, strengthening balance sheet Volatus will host a webinar and live Q&A on Monday, June 2, 2025, at 8 am ET (see registration link below). TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the three months ended March 31, 2025 (Q1 2025).
Volatus Aerospace Inc. Announces Shares-for-Debt Transaction
/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, May 22, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A2JEQU) (“Volatus” or the “Company”), a leader in global aerial solutions, is pleased to announce a proposed shares-for-debt settlement aimed at enhancing shareholder value and strengthening the Company's balance sheet. The Company has reached an agreement, subject to receipt of TSX Venture Exchange (“TSXV”) approval, with holders of unsecured non-convertible debentures of Volatus Aerospace Corp., a wholly-owned subsidiary of the Company (the “Debentures”), to settle the outstanding principal and accrued and unpaid interest owing under the Debentures as at the maturity date, being May 23, 2025, in the aggregate amount of $446,400 in consideration for the issuance of an aggregate of 3,720,000 units of the Company (the “Settlement Units”) at a deemed price of $0.12 per Settlement Unit (the “Shares-for-Debt Transaction”).
Volatus Aerospace Inc. Completes Shares-for-Debt Settlement of Unsecured Convertible Debentures
/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: ABB) ("Volatus" or the “Company"), a leader in global aerial solutions, is pleased to announce that, further to its press release dated April 11, 2025, the Company has completed its previously announced shares-for-debt transaction (the “Shares-for-Debt Transaction”) and issued a total of 20,174,280 common voting shares in the capital of the Company (the “Common Shares”) and 17,640,000 Common Share purchase warrants (each a “Warrant”) settling an aggregate debt of $3,026,142.00 owing to holders of unsecured convertible debentures of the Company (the “Debentures”) issued pursuant to a debenture indenture dated May 11, 2023 between the Company and TSX Trust Company. To give effect to the Shares-for-Debt Transaction, the Company and TSX Trust Company, as trustee, entered into a third supplemental indenture to the debenture indenture governing the Debentures.
Volatus Releases Fourth Quarter and Fiscal Year 2024 Financial Results
TORONTO, April 30, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQB:TAKOF) (Frankfurt:A3DP5Y/ABBA.F) ("Volatus" or "the Company"), a leader in aerial solutions, is pleased to announce its financial results for the twelve-month period and fourth quarter ended Dec 31, 2024 (“FY 2024” and “Q4 2024”, respectively). All dollar figures are stated in Canadian dollars, unless otherwise indicated.
Volatus Announces $2,000,000 Financing
Not for distribution to United States newswire services or for dissemination in the United States. TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce that it has filed an offering document in connection with a non-brokered private placement of up to 16,666,667 units of the Company (the “Units”) at a price of $0.12 per Unit (the “Issue Price”) for gross proceeds of up to $2,000,000.04 (the “LIFE Financing”).
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annua
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML models Actimab-A is the only CD33 targeted radiotherapy with Actinium-225 isotope payload in development for AML and other myeloid malignancies Actimab-A is currently being advanced in several combination studies including a Phase 2/3 trial in combination with CLAG-M in relapsed/refractory AML and in combination with Venetoclax and ASTX-727, an oral hypomethylating agent from Taiho Oncology in frontline AML under a CRADA with the NCI NEW YORK , April 28, 2025 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today highlighted data presented at the American Association for Cancer Research (AACR) Annual Meeting supporting Actimab-A's mutation agnostic antileukemic effect and backbone therapy potential in preclinical acute myeloid leukemia (AML) models. The preclinical data demonstrate that the combination of Actimab-A with standard of care AML therapies including menin and FLT3 inhibitors and the hypomethylating agent (HMA) azacitidine resulted in significant antileukemic activity in AML cells lines with FLT3, NPM1, KMT2A and TP53 mutations.
Senti Bio's SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML
Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and preliminary recommended Phase 2 dose (RP2D) identified 5 of 7 best overall response evaluable patients achieved ORR (3 CR, 1 CRh and 1 morphologic leukemia-free state) across all dose cohorts, including 1 CR and 1 CRh in 3 patients in preliminary RP2D cohort 4 of 4 cCR patients were measurable residual disease (MRD) negative as assessed by local standard of care Early deep responses with SENTI-202 noted across dose levels with all cCRs ongoing as of the data cut and longest durability of 8+ months Company to host webcast to discuss the new Phase 1 SENTI-202 data today, April 28th at 8:30 AM ET; Register Here Announces certain preliminary first quarter 2025 financial results and provides pipeline update SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today reported additional positive preliminary data from a Phase 1 clinical trial of SENTI-202, a potential first-in-class off-the-shelf Logic Gated selective CD33 OR FLT3 NOT EMCN chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for the treatment of relapsed/refractory (R/R) hematologic malignancies including acute myeloid leukemia (“AML”).
Volatus Aerospace Gains Clearance for High-Value RPAS Deployment in Oil & Gas Sector
TORONTO, April 15, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A3DP5Y/ABBA.F) is pleased to announce that last week it was approved by two leading North American oil and gas companies to provide drone-based aerial services in support of critical energy infrastructure. This approval follows a comprehensive flight operations review process conducted to validate Volatus' operational readiness and safety protocols.
Volatus Aerospace Inc. Announces Shares-for-Debt Settlement of Unsecured Convertible Debentures to Strengthen Balance Sheet
/ NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES / TORONTO, April 11, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV: FLT) (OTCQX: TAKOF) (Frankfurt: A2JEQU) ("Volatus" or the “Company"), a leader in global aerial solutions, is pleased to announce a proposed shares-for-debt settlement aimed at enhancing shareholder value and strengthening the Company's balance sheet. Effective April 10, 2025, the Company has reached an agreement, subject to receipt of TSX Venture Exchange (“TSXV”) approval, with the holders of convertible debentures issued pursuant to a debenture indenture dated May 11, 2023 (the “Debenture Indenture”) between the Company and TSX Trust Company as trustee (the “Trustee”).
